The Food and Drug Administration Saturday authorized the emergency use of Everlywell, Inc.’s COVID-19 Test Home Collection Kit. The product is a standalone, at-home, nasal-swab sample collection kit that can be sent to specified labs for subsequent COVID-19 diagnostic testing using certain tests separately authorized by FDA for use with the new kit.

The labs authorized to test specimens collected using the authorized kit are Fulgent Therapeutics and Assurance Scientific Laboratories. Individuals must be screened via an online questionnaire, the results of which are reviewed by health care professionals, in order to gain access to the kit.

Results are returned to the patient through Everlywell’s independent physician network and online portal.

Related News Articles

Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…